Immunic Names Veteran Neurologist Michael Panzara as CMO Before Phase 3 ENSURE Readout
Immunic has appointed neurologist Michael A. Panzara as Chief Medical Officer to oversee clinical development and regulatory strategy for oral MS therapy vidofludimus calcium. Panzara’s 25-year track record includes clearances for LEMTRADA, AUBAGIO, TYSABRI and Tecfidera as Immunic prepares for its pivotal Phase 3 ENSURE trial readout expected within months.
1. Chief Medical Officer Appointment
Immunic has named Michael A. Panzara as Chief Medical Officer, succeeding co-founder Andreas Muehler who will remain as a consultant. Panzara will lead clinical development and regulatory affairs for vidofludimus calcium, integrating medical strategy with upcoming trial milestones and commercial planning.
2. Track Record in MS Drug Development
Panzara brings over 25 years of experience in neurology drug development, having overseen global regulatory clearances for LEMTRADA and AUBAGIO at Sanofi Genzyme, and led clinical programs for TYSABRI, AVONEX, PLEGRIDY and Tecfidera at Biogen. His background positions him to navigate late-stage trial design and approval pathways.
3. Next Steps for ENSURE Phase 3 Trial
Under Panzara’s oversight, Immunic will advance its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis, with topline data expected within months. Success in these readouts could trigger regulatory filings and shape the company’s valuation ahead of potential commercialization.